



VacZine Analytics

Bringing life to vaccine strategy...

MenACWY vaccines

Country roll-out

October 2008

Meningitis vaccine adoption: Major EU5 and US

	Market type	NIP approved	Routine schedule	Catch-up	Product
US	NIP	2005	Single dose 11-12yrs	13-18yrs*	Menactra (ACWY)**
UK	NIP	1999	Two/three doses 3-12mos Single dose 15-17yrs (1999 only)	<18yrs (2000-2001)	MCC Menitorix (Hib/C)***
France	Outbreak control				MCC
Germany	NIP	2006	Single dose 12-23mos	None	MCC
Spain	NIP	2000	Two/three doses 2-6mos	7m-19yrs (2001-2004)	MCC
Italy	Private		None		
Japan			None		

MCC = meningitis C conjugated vaccine (Meningitec/CRM197/Wyeth; Menjugate/CRM197/Novartis and NeisVac-C/tetanus toxoids/Baxter. In infant schedule, Meningitec & Menjugate three doses, NeisVac-C two doses)

*Also recommended for college freshmen and populations aged 2-55yrs at increased risk.

**Menomune (ACYW polysaccharide vaccine/Sanofi Pasteur) licensed in the United States since 1978 but not recommended for routine vaccination

***From Sep 2006 Hib/C replaced third dose for infants

Meningitis vaccine adoption: other countries

	Market type	NIP approved	Routine schedule	Catch-up	Product
Russia					
China	NIP	1980s	Yes, unknown	Unknown	Polysaccharide Vaccine A and AC (China National Biotech Group)
India					
Brazil	Outbreak control				Serogroup C vaccine campaigns conducted in Rio de Janeiro (1994-95) and Santa Catarina (1996)
Mexico					
Australia	NIP	2003	Single dose 12m	Catch up in 1-19 years until June 2006	MCC
Canada	NIP	2002	Three doses 2-6mos or single dose 12mos*	1-16yrs (from 2001)	MCC

MCC = meningitis C conjugated vaccine (Meningitec/CRM197/Wyeth; Menjugate/CRM197/Novartis and NeisVac-C/tetanus toxoids/Baxter. In infant schedule, Meningitec & Menjugate three doses, NeisVac-C two doses)

*varies by territory

About VacZine Analytics:

VacZine Analytics is a brand new research consultancy based in the United Kingdom. Its aim is to provide high quality-disease and commercial analysis to those working within or in collaboration with the vaccine industry.

- © With our product lines:
 - DiseaseINFOPACK
 - OpportunitySCAN
 - MarketVIEW
 - ExpertREACT
 - VaccineSTATS

Our key focus is helping clients to build the case for developing new vaccines.

All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.



VacZine Analytics

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel. +44 (0) 1279 654514

e-mail: info@vacZine-analytics.com